Breaking News

Horizon, Promega in Predictive Disease Model Pact

Partnership aims to enable personalized drug development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Horizon Discovery Ltd. has entered a strategic partnership agreement with Promega Corp. for the delivery of endogenous gene reporting capabilities with Promega’s luciferase and HaloTag reporter technologies, using Horizon’s homologous recombination-based precision genome editing technology (rAAV GENESIS). The partnership aims to develop next-generation predictive human disease models as they occur in patient tumors. To date, Horizon has applied its rAAV gene-editing platform to reconstitute mor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters